JPRN-jRCT1011220023
Recruiting
N/A
A prospective observational study to investigate real-world IMmunogenicity of theraPeutic Antibodies and to identify faCTors responsible for the interindividual variability - IMPACT study
Fukudo Masahide0 sites300 target enrollmentOctober 29, 2022
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Fukudo Masahide
- Enrollment
- 300
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects whose medical care and prognostic information can be obtained from medical records
Exclusion Criteria
- •Subjects presenting with any of the following will be excluded from the study:
- •1\. Subjects who requested non\-participation in this study based on a published opt\-out document.
- •2\. Subjects who are participating in or interested in participating in other clinical trials during the study period.
- •3\. Subjects who are judged as not suitable for participating in this study by treating physician.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
An observational multicenter study to assess the risk factor profile of early Coronary Artery Disease (CAD) in IndiansCTRI/2012/12/003232otus Clinical Research Academy2,000
Completed
N/A
A prospective observational study to investigate the effect of rehabilitation for cancer patients in palliative care units in Japan: a pilot-feasibility studyJPRN-UMIN000034560Ashiya Municipal Hospital50
Completed
N/A
A prospective observational study to investigate the relationship between instability of glucose variability with age and diabetes-related complications or disorders in Japanese patients with type 2 diabetesType 2 diabetesJPRN-UMIN000044304Hokkaido University Hospital200
Completed
N/A
Aetiology of preoperative anaemia in cardiac surgeryPreoperative anaemiaHaematological DisordersISRCTN49461366Papworth Hospital (UK)200
Completed
N/A
A prospective observational study to investigate the safety of SARS-CoV-2 vaccine in patients with lung cancer who are treated or will be treated with anticancer medication (OLCSG2102)ung cancerJPRN-UMIN000043918Iwakuni Clinical Center500